Article

Six-gene signature predicts survival in advanced PCa

Researchers from Mount Sinai School of Medicine in New York say they have identified a six-gene signature that can be used in a test to predict survival in men with aggressive prostate cancer.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
DNA helix | Image Credit: © Radomir Jovanovic - stock.adobe.com
Betty Wang, MD, and Laura Bukavina, MD, MPH, MSc, discuss ctDNA's role in NMIBC treatment decisions
Andrea Pezzella, MD, URPS, FACOG, discusses Neuspera's integrated sacral neuromodulation system
Andrea Pezzella, MD, URPS, FACOG, discusses Neuspera's integrated sacral neuromodulation system
The Growing Call for Combination Therapy in NMIBC Treatment
The Growing Call for Combination Therapy in NMIBC Treatment
Optimizing NMIBC Treatment Through Sequencing and Patient Preference
Optimizing NMIBC Treatment Through Sequencing and Patient Preference
Mina Fam, MD, on managing expectations around testosterone replacement therapy
Mina Fam, MD, on managing expectations around testosterone replacement therapy
Justin Dubin, MD, on the role for AI in patient education
Justin Dubin, MD, on the role for AI in patient education
Considerations for pre-procedure urinalysis, periprocedural antibiotics for onabotA
Considerations for pre-procedure urinalysis, periprocedural antibiotics for onabotA
Medical stethoscope and dollar bills | Image Credit: © Kuzmick - stock.adobe.com
TMT for bladder cancer: Balancing cost and quality of life
Anne Schuckman, MD, outlines current challenges in NMIBC care
Anne Schuckman, MD, outlines current challenges in NMIBC care
1 expert is featured in this series.
Managing Abiraterone Intolerance: Alternative Dosing Strategies in Practice
Related Content
Patient talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
July 10th 2025

FDA grants breakthrough device designation for ArteraAI Prostate tool

Benjamin P. Saylor Hannah Clarke
“This designation is a powerful validation of our software's potential to transform how we treat cancer,” said Andre Esteva, CEO of Artera.
Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD
June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD
Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
July 10th 2025

EMBARK: Significant OS gains seen with enzalutamide plus leuprolide in nmHSPC

Benjamin P. Saylor
According to the news release, detailed OS data from EMBARK are set to be presented at an upcoming medical conference.
Pearls & Perspectives: Sexual Health in MSM, with Joshua R. Gonzalez, MD
June 19th 2025

Pearls & Perspectives: Sexual Health in MSM, with Joshua R. Gonzalez, MD

Amy M. Pearlman, MD
The conversation covers practical, case-based strategies for counseling MSM patients.
Shot of a doctor showing a patient some information on a digital tablet | Image Credit: © bongkarn - stock.adobe.com
July 9th 2025

Leva System adds Mayo Clinic overactive bladder content

Benjamin P. Saylor Hannah Clarke
Among the content is additional information on types of urinary incontinence, ways to control urgency, and frequently asked questions about a healthy bladder.
Optimizing SNM: PEER trials investigate potential of SNM lead sensing
July 9th 2025

Optimizing SNM: PEER trials investigate potential of SNM lead sensing

Colin Goudelocke, MD Hannah Clarke
Colin M. Goudelocke, MD, discusses the PEER trials, which are assessing the safety and efficacy of SNM lead sensing for optimizing SNM programming.
© 2025 MJH Life Sciences

All rights reserved.